IL128850D0 - Medical treatment - Google Patents

Medical treatment

Info

Publication number
IL128850D0
IL128850D0 IL12885097A IL12885097A IL128850D0 IL 128850 D0 IL128850 D0 IL 128850D0 IL 12885097 A IL12885097 A IL 12885097A IL 12885097 A IL12885097 A IL 12885097A IL 128850 D0 IL128850 D0 IL 128850D0
Authority
IL
Israel
Prior art keywords
medical treatment
medical
treatment
Prior art date
Application number
IL12885097A
Other versions
IL128850A (en
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GBGB9619757.9A priority Critical patent/GB9619757D0/en
Application filed by Knoll Ag filed Critical Knoll Ag
Priority to PCT/EP1997/005039 priority patent/WO1998011884A1/en
Publication of IL128850D0 publication Critical patent/IL128850D0/en
Publication of IL128850A publication Critical patent/IL128850A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/866Diabetes
IL12885097A 1996-09-21 1997-09-15 Pharmaceutical composition comprising substituted or unsubstituted n, n-1[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride monohydrate for reducing insulin resistance in humans and its manufacture IL128850A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB9619757.9A GB9619757D0 (en) 1996-09-21 1996-09-21 Chemical process
PCT/EP1997/005039 WO1998011884A1 (en) 1996-09-21 1997-09-15 Use of sibutramine analogues to prevent the development of diabetes

Publications (2)

Publication Number Publication Date
IL128850D0 true IL128850D0 (en) 2000-01-31
IL128850A IL128850A (en) 2003-07-31

Family

ID=10800326

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12885097A IL128850A (en) 1996-09-21 1997-09-15 Pharmaceutical composition comprising substituted or unsubstituted n, n-1[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride monohydrate for reducing insulin resistance in humans and its manufacture

Country Status (25)

Country Link
US (3) US6174925B1 (en)
EP (1) EP0927028A1 (en)
JP (1) JP2001503737A (en)
KR (1) KR20000048501A (en)
CN (1) CN1237905A (en)
AU (1) AU724488B2 (en)
BG (1) BG64473B1 (en)
BR (1) BR9711517A (en)
CA (1) CA2266401C (en)
CZ (1) CZ93699A3 (en)
GB (1) GB9619757D0 (en)
HR (1) HRP970505A2 (en)
HU (1) HU9904026A3 (en)
ID (1) ID18320A (en)
IL (1) IL128850A (en)
NO (1) NO991358D0 (en)
NZ (1) NZ334580A (en)
PL (1) PL332305A1 (en)
RU (1) RU2245709C2 (en)
SK (1) SK31999A3 (en)
TR (1) TR199900618T2 (en)
TW (1) TW580385B (en)
UA (1) UA64726C2 (en)
WO (1) WO1998011884A1 (en)
ZA (1) ZA9708450B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
JP2000080047A (en) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd Medicine
DE69929996T2 (en) * 1998-06-30 2006-11-16 Takeda Pharmaceutical Co. Ltd. Pharmaceutical agent for the treatment of diabetes
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
AR023700A1 (en) * 1998-11-12 2002-09-04 Smithkline Beecham Plc A process for preparing a pharmaceutical composition comprising an insulin sensitizer
NZ511614A (en) * 1998-11-12 2003-12-19 Smithkline Beecham P Modified release pharmaceutical composition containing the insulin sensitiser 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and the antidiabetic agent metaformin
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6680344B1 (en) 1999-06-01 2004-01-20 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
US6723717B1 (en) 1999-06-01 2004-04-20 The University Of Texas Southwestern Medical Center Sulfur-containing thyroxane derivatives and their use as hair growth promotors
US6646005B1 (en) 1999-06-01 2003-11-11 The University Of Texas Southwestern Medical Center Method of treating hair loss using sulfonyl thyromimetic compounds
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
PL376577A1 (en) 2002-06-17 2006-01-09 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
MXPA05003355A (en) * 2002-10-05 2005-10-18 Hanmi Pharm Ind Co Ltd Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate.
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
AR045330A1 (en) * 2003-08-07 2005-10-26 Sb Pharmco Inc Oral dosage form, process for their preparation and use of the compound 5- (4- (2- (N-methyl-N- (2-pyridyl) amino) ethoxy) benzyl) thiazolidin-2,4-dione or a salt or pharmaceutically acceptable solvate of the same to prepare
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
PT1677792E (en) * 2003-10-31 2016-02-09 Takeda Pharmaceutical Solid preparation comprising pioglitazone, glimepiride and a polyoxyethylene sorbitan fatty acid ester
KR100627687B1 (en) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 Composition containing sibutramine free base and manufacturing method thereof
RU2430913C2 (en) 2006-01-06 2011-10-10 Сепракор Инк. Cycloalkylamines as monoamine reuptake inhibitors
WO2008034142A2 (en) 2006-09-15 2008-03-20 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
KR100812538B1 (en) * 2006-10-23 2008-03-11 한올제약주식회사 Controlled release complex formulation comprising metformin and glimepiride
WO2008063024A1 (en) * 2006-11-22 2008-05-29 Sk Chemicals Co., Ltd. Inclusion complex of sibutramine and beta-cyclodextrin
JP5649825B2 (en) 2007-01-31 2015-01-07 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Stabilized p53 peptides and methods of use thereof
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
CN108570097A (en) 2010-08-13 2018-09-25 爱勒让治疗公司 Peptidomimetic macrocyclic compound
MX358886B (en) 2011-10-18 2018-08-31 Aileron Therapeutics Inc Peptidomimetic macrocyles.
RU2642074C2 (en) 2011-12-30 2018-01-24 Ревива Фармасьютикалс, Инк. Compositions, synthesis and methods for application of phenylcycloalkylmethylamine derivatives
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN104159595A (en) 2012-02-15 2014-11-19 爱勒让治疗公司 Peptidomimetic macrocycles
EP2914256B1 (en) 2012-11-01 2019-07-31 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
MX2017003797A (en) 2014-09-24 2017-06-15 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof.
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (en) * 1988-03-31 1997-11-12 科研製薬株式会社 Brain function improver
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
WO1995010292A1 (en) 1993-10-14 1995-04-20 Biomedica California, Inc. Diabetes treatment and prophylaxis
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process

Also Published As

Publication number Publication date
BG103277A (en) 2000-01-31
NO991358L (en) 1999-03-19
CA2266401C (en) 2007-01-30
KR20000048501A (en) 2000-07-25
CA2266401A1 (en) 1998-03-26
SK31999A3 (en) 1999-12-10
CZ93699A3 (en) 1999-08-11
BG64473B1 (en) 2005-04-30
GB9619757D0 (en) 1996-11-06
UA64726C2 (en) 2000-08-15
US20040077730A1 (en) 2004-04-22
CN1237905A (en) 1999-12-08
JP2001503737A (en) 2001-03-21
NZ334580A (en) 2000-09-29
US6617360B1 (en) 2003-09-09
US6174925B1 (en) 2001-01-16
IL128850A (en) 2003-07-31
WO1998011884A1 (en) 1998-03-26
EP0927028A1 (en) 1999-07-07
BR9711517A (en) 1999-08-24
ID18320A (en) 1998-03-26
AU724488B2 (en) 2000-09-21
RU2245709C2 (en) 2005-02-10
PL332305A1 (en) 1999-08-30
TW580385B (en) 2004-03-21
AU4774097A (en) 1998-04-14
TR199900618T2 (en) 1999-06-21
HU9904026A3 (en) 2000-07-28
HRP970505A2 (en) 1998-08-31
NO991358D0 (en) 1999-03-19
HU9904026A2 (en) 2000-05-28
ZA9708450B (en) 1999-03-19

Similar Documents

Publication Publication Date Title
DE69515632T2 (en) Dental treatment system
GB2287652B (en) Efficient photodynamic treatment
GB2321193B (en) Endoscopic treatment tool
GB2298440B (en) Well treatment
PL331901A1 (en) Syringe
NZ298293A (en) Medical connector
HU9602271D0 (en) Surgical apparatus
IL114995A (en) Medical anchor
DE29623747U1 (en) Medical facility
AU4025397A (en) Treatment of pain
GB9601724D0 (en) Therapeutic agents
GB9611074D0 (en) Surgical apparatus
EP0715863A3 (en) Catheter
IL114352D0 (en) Catheter
AU3294497A (en) Implantable medical device
PL185137B1 (en) Syringe
ZA9509616B (en) Facial tissue carpack
ZA9706562B (en) Isobutylgaba and its derivatives for the treatment of pain.
AP200202661A0 (en) Combination therapy for oesteoporosis
EP0800795A4 (en) Medical coagulation apparatus
IL113872A (en) Tissue monitor
EP0752844A4 (en) Human osteoclast-derived cathepsin
ZA9600740B (en) Skin treatment composition
EP0879279A4 (en) Diabetes therapy
GB9501218D0 (en) Medical devices

Legal Events

Date Code Title Description
HCA Change of name of proprietor(s) after amalgamation
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees